NL-OMON24018Not yet recruitingNot Applicable
Effects of GLP1 agonist liRAglutiDE in patients with antispychotic-drUgs-associATEd diabetes mellitus
MC Utrecht0 sites50 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Informed consent obtained before any trial related activities
- •Males or females aged 18 years or older
Exclusion Criteria
- •Any type of diabetes present before the use of anti-psychotic drugs
- •Use of glucose-lowering medication other than metformin
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Assessing the efficacy and safety of the GLP1-agonist liraglutide in patients who developed diabetes as a consequence of the use of anti-psychotic drugsEUCTR2013-005395-18-NLniversity Medical Center Utrecht
Withdrawn
Phase 4
Effects of GLP1 agonist liraglutide in patients with antipsychotic-drugs-associated diabetes mellitus10018424Diabetes MellitusNL-OMON40321Interne geneeskunde50
Active, not recruiting
Phase 1
EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAPeripheral Artery Disease and type 2 diabetes mellitusMedDRA version: 20.0Level: LLTClassification code 10053246Term: Type II diabetes peripheral angiopathySystem Organ Class: 100000004866EUCTR2020-002940-22-ITA.O.U. Università degli Studi della Campania Luigi Vanvitelli50
Terminated
Phase 3
Study of Liraglutide in Individuals With Type 2 Diabetes Using InsulinType 2 DiabetesNCT01628445University of Manitoba52
Unknown
Not Applicable
Effect of Liraglutide on Clock GenesType 2 DiabetesNCT02783196Tel Aviv University14